Serveur d'exploration Tocilizumab

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Languedoc-Roussillon71
S. Rouanet4
Languedoc-Roussillon Sauf S. Rouanet" 68
S. Rouanet Sauf Languedoc-Roussillon" 1
Languedoc-Roussillon Et S. Rouanet 3
Languedoc-Roussillon Ou S. Rouanet 72
Corpus6869
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 3.
Ident.Authors (with country if any)Title
002A50 L. Gossec [France] ; S. Rouanet ; G. Steinberg ; B. Combe [France]THU0063 Does biologic treatment modify the relationship of the variables associated with fatigue in patients with rheumatoid arthritis? The peps study of tocilizumab in real life
002E02 J. Sellam [France] ; S. Rouanet ; H. Hendel-Chavez ; S. Marion-Thore [France] ; C. Miceli-Richard ; B. Combe [France] ; J. Sibilia [France] ; X. Le Loët ; J. Tebib ; G. Chiocchia [France] ; R. Jourdan ; M. Dougados [France] ; Y. Taoufik ; X. MarietteFRI0247 Serum level of interleukin 33, a novel independent predictive biomarker of clinical response to rituximab in rheumatoid arthritis: results from the smart trial
003567 A. Ruyssen-Witrand [France] ; S. Rouanet [France] ; B. Combe [France] ; M. Dougados [France] ; X. Le Loët [France] ; J. Sibilia [France] ; J. Tebib [France] ; X. Mariette [France] ; A. Constantin [France]Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021